Skip to main
VCYT
VCYT logo

Veracyte (VCYT) Stock Forecast & Price Target

Veracyte (VCYT) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 47%
Hold 7%
Sell 7%
Strong Sell 0%

Bulls say

Veracyte Inc. demonstrated significant growth in genomic test volume, increasing by 25% to a total of 39,107 tests, bolstered by a substantial 45% rise in urology tests from its Decipher platform. The company also saw a notable improvement in financial performance, with adjusted EBITDA margin advancing by 690 basis points year-over-year and testing revenue reaching $112.2 million, marking a 24% increase in the fourth quarter. Additionally, management projects continued improvement in adjusted EBITDA margins for 2025, alongside strong potential drivers from expanding sales of existing tests and improved operational cash flow.

Bears say

Veracyte Inc. faces a negative outlook primarily due to slowing revenue growth, with an anticipated growth rate of only 10-15%, primarily attributed to underperforming Afirma and Decipher tests. Despite a reduction in selling, general and administrative expenses, as well as improvements in non-GAAP operating and adjusted EBITDA margins, the overall testing revenue growth decelerated from 29% in 3Q24 to 21% in 4Q24, indicating potential market challenges. Additionally, uncertainty surrounding the potential exit from the VCYT subsidiary could further dampen consensus revenue expectations for 2025, leading to concerns about the company's long-term financial stability.

Veracyte (VCYT) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 47% recommend Buy, 7% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Veracyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Veracyte (VCYT) Forecast

Analysts have given Veracyte (VCYT) a Buy based on their latest research and market trends.

According to 15 analysts, Veracyte (VCYT) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $36.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $36.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Veracyte (VCYT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.